Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
McKesson
US Army
Queensland Health
Fish and Richardson
Covington

Generated: September 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,722,684

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,722,684
Title:1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT.sub.3 and 5-HT.sub.1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients. ##STR00001##
Inventor(s): Bang-Andersen; Benny (Copenhagen S., DK), Faldt; Andre (Ishoj, DK), Mork; Arne (Malov, DK), Lopez de Diego; Heidi (Naerum, DK), Holm; Rene (Jyllinge, DK), Stensbol; Tine Bryan (Vaerlose, DK), Moore; Nicholas (Delmar, NY)
Assignee: H. Lundbeck A/S (Valby, DK)
Application Number:12/301,061
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,722,684
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,722,684

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-001 Sep 30, 2013 RX Yes No   Try a Free Trial   Try a Free Trial Y Y   Try a Free Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-002 Sep 30, 2013 RX Yes No   Try a Free Trial   Try a Free Trial Y Y   Try a Free Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 DISCN Yes No   Try a Free Trial   Try a Free Trial Y Y   Try a Free Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes   Try a Free Trial   Try a Free Trial Y Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,722,684

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2006 00824Jun 16, 2006
Denmark2006 01223Sep 22, 2006
Denmark2006 01384Oct 25, 2006
Denmark2007 00427Mar 20, 2007
PCT Information
PCT FiledJune 15, 2007PCT Application Number:PCT/DK2007/050075
PCT Publication Date:December 21, 2007PCT Publication Number: WO2007/144005

International Family Members for US Patent 8,722,684

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 061481   Try a Free Trial
Argentina 065797   Try a Free Trial
Austria 495745   Try a Free Trial
Austria 540941   Try a Free Trial
Australia 2007260355   Try a Free Trial
Australia 2008228638   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Queensland Health
AstraZeneca
Argus Health
Julphar
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.